Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
belantamab + belantamab mafodotin + pomalidomide + dexamethasone
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
unconjugated belantamab + pomalidomide + dexamethasone + Blenrep is an investigational combination regimen developed by GSK for the treatment of relapsed/refractory multiple myeloma. This four-drug regimen combines two anti-BCMA (B-cell maturation antigen) agents—the unconjugated (naked) monoclonal antibody belantamab and the antibody-drug conjugate (ADC) belantamab mafodotin (Blenrep)—with the immunomodulatory agent pomalidomide and the corticosteroid dexamethasone. The rationale behind this combination is to enhance anti-myeloma activity by utilizing both the direct cytotoxicity of the ADC's auristatin F payload and the immune-mediated effects of the naked antibody and pomalidomide. The regimen is currently being evaluated in the DREAMM-5 platform trial (NCT04091126), specifically in Part 3, to determine if the addition of the unconjugated antibody to the standard-of-care backbone can improve clinical outcomes in patients who have received prior therapies.
- Other names
- unconjugated belantamab + pomalidomide + dexamethasone + Blenrep
02
Targets
BCMA (B-cell maturation antigen)CRBN (Cereblon)GR (Glucocorticoid receptor)IKZF1 (Ikaros family zinc finger protein 1)IKZF3 (Zinc finger protein Aiolos)
Beyond the preview
Go deeper on belantamab + belantamab mafodotin + pomalidomide + dexamethasone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on belantamab + belantamab mafodotin + pomalidomide + dexamethasone.